"Hydroxychloroquine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
Below are MeSH descriptors whose meaning is more general than "Hydroxychloroquine".
Below are MeSH descriptors whose meaning is more specific than "Hydroxychloroquine".
This graph shows the total number of publications written about "Hydroxychloroquine" by people in Harvard Catalyst Profiles by year, and whether "Hydroxychloroquine" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 3 | 4 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 3 | 6 |
| 2015 | 2 | 2 | 4 |
| 2016 | 1 | 6 | 7 |
| 2017 | 4 | 2 | 6 |
| 2018 | 9 | 3 | 12 |
| 2019 | 2 | 4 | 6 |
| 2020 | 31 | 41 | 72 |
| 2021 | 14 | 17 | 31 |
| 2022 | 7 | 17 | 24 |
| 2023 | 4 | 6 | 10 |
Below are the most recent publications written about "Hydroxychloroquine" by people in Profiles.
-
Misinformation, Trust, and Use of Ivermectin and Hydroxychloroquine for COVID-19. JAMA Health Forum. 2023 09 01; 4(9):e233257.
-
Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study. J Drugs Dermatol. 2023 08 01; 22(8):840-843.
-
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review. Arthritis Care Res (Hoboken). 2023 11; 75(11):2295-2305.
-
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations. Clin Transl Sci. 2023 07; 16(7):1243-1257.
-
Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. Int J Dermatol. 2023 09; 62(9):e473-e474.
-
Assessment of hydroxychloroquine use and QT interval duration in female patients with frontal fibrosing alopecia. Int J Dermatol. 2023 09; 62(9):e509-e510.
-
Hydroxychloroquine Dose and Risk of Systemic Lupus Erythematosus Flares-Reply. JAMA. 2023 02 28; 329(8):686-687.
-
Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med. 2023 02; 176(2):166-173.
-
Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials. Clin Transl Sci. 2023 03; 16(3):524-535.
-
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA. 2023 01 03; 329(1):39-51.